$UNH 8-K earnings — Q2 FY26

Q2 revenues hit $112.0B with adjusted EPS of $6.38, beating prior expectations. The medical cost ratio was 86.7%, reflecting pricing discipline and favorable prior-period development of $860M. Full-year adjusted EPS guidance was raised to $19.50-$20.00 from prior range, driven by year-to-date performance and improved outlook. Cash from operations was $11.1B, or 1.9x net income.

Q2 revenues hit $112.0B with adjusted EPS of $6.38, beating prior expectations. The medical cost ratio was 86.7%, reflecting pricing discipline and favorable prior-period development of $860M. Full-year adjusted EPS guidance was raised to $19.50-$20.00 from prior range, driven by year-to-date performance and improved outlook. Cash from operations was $11.1B, or 1.9x net income.